Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...

Biogen Inc. (NASDAQ:BIIB ... but I think we feel particularly excited about Felzartamab and the potential that this could have in rare kidney disease. And of course, then we have a whole phase ...

Biogen Inc. (NASDAQ ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the race really that we are ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Biogen's development organization had another ... is only the third agent with a positive global Phase III study in SLE. Additionally, Felzartamab was granted orphan drug designation in the ...

Thanks, Jennifer, and good morning, and welcome to Biogen's fourth-quarter and full ... but I think we feel particularly excited about felzartamab and the potential this could have in rare kidney ...